PLAT and myocardial infarction: Tenecteplase is a modified recombinant tissue plasminogen activator molecule (tPA) engineered to improve efficacy through increased affinity binding to fibrin, greater resistance to inactivation by plasminogen activator inhibitor-1, no procoagulant effects, and longer free plasma half-life [3].These pharmacodynamic differences result in more rapid coronary reperfusion, with tenecteplase now the first-line IV thrombolytic for myocardial infarction [4-5].